SCP vs HUSLS for Pelvic Organ Prolapse Repair

Sponsor
Loma Linda University (Other)
Overall Status
Recruiting
CT.gov ID
NCT02800512
Collaborator
(none)
112
1
2
68
1.6

Study Details

Study Description

Brief Summary

The purpose of this study is to compare the effectiveness of R-SCP versus HUSLS for treatment of pelvic organ prolapse.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Robotic sacrocolpopexy
  • Procedure: high uterosacral ligament suspension
N/A

Detailed Description

To compare the effectiveness of Robotic Sacrocolpopexy versus vaginal High Uterosacral Ligament Suspension for treatment of pelvic organ prolapse. Both surgeries are standard of care and are equally and widely used throughout the country with well known safety and efficacy.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
112 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
Robotic Sacrocolpopexy Versus High Uterosacral Ligament Suspension: A Randomized Trial
Actual Study Start Date :
Dec 1, 2016
Anticipated Primary Completion Date :
Aug 1, 2022
Anticipated Study Completion Date :
Aug 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Sacrocolpopexy

Robotic sacrocolpopexy

Procedure: Robotic sacrocolpopexy
Sacrocolpopexy is a procedure to surgically correct vaginal vault prolapse where mesh is used to hold the vagina in the correct anatomical position. Robotic assistance is a minimally invasive method to perform this abdominal procedure.
Other Names:
  • R-SCP
  • Active Comparator: HUSLS

    Vaginal high uterosacral ligament suspension

    Procedure: high uterosacral ligament suspension
    Utilizing uterosacral ligaments to support the vaginal cuff can be performed vaginally-by passing sutures bilaterally through the uterosacral ligaments. near the level of the ischial spine. HUSLS is a vaginal minimally invasive procedure for POP.
    Other Names:
  • HUSLS
  • Outcome Measures

    Primary Outcome Measures

    1. Pelvic Organ Prolapse Quantification (pop-q) to asses change post operatively [3 month post operative]

      Pelvic organ prolapses are graded with the Pelvic Organ Prolapse Quantification (POP-Q) System.

    2. Pelvic Organ Prolapse Quantification (pop-q) to asses change post operatively [6 month post operative]

      Pelvic organ prolapses are graded with the Pelvic Organ Prolapse Quantification (POP-Q) System.

    3. Pelvic Organ Prolapse Quantification (pop-q) to asses change post operatively [12 month post operative]

      Pelvic organ prolapses are graded with the Pelvic Organ Prolapse Quantification (POP-Q) System.

    Secondary Outcome Measures

    1. questionnaires PFDI-7 [6 month post operative]

      Subject will fill out the PFDI-7 questionnaire

    2. questionnaires PFDI-7 [12 month post operative]

      Subject will fill out the PFDI-7 questionnaire

    3. questionnaires PFIQ-20 [6 month post operative]

      Subject will fill out the PFIQ-20 questionnaire

    4. questionnaires PFIQ-20 [12 month post operative]

      Subject will fill out the PFIQ-20 questionnaire

    5. questionnaires PISQ-12 [6 month post operative]

      Subject will fill out the PISQ-12 questionnaire

    6. questionnaires PISQ-12 [12 month post operative]

      Subject will fill out the PISQ-12 questionnaire

    7. questionnaires PGI-I [6 month post operative]

      Subject will fill out the PGI-I

    8. questionnaires PGI-I [12 month post operative]

      Subject will fill out the PGI-I

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 100 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • 18 Years of age or older

    • Signed Informed Consent

    • Symptomatic pelvic organ prolapse,

    • Willing and able to complete all study visit

    Exclusion Criteria:
    • Non-High Uterosacral Ligament Suspension (unable to do HUSLS at time of surgery),

    • Dementia or considered unable to complete questionnaires

    1. Hx of Alzheimer Disease

    2. Hx multiple strokes or other neurologic condition

    3. Caregiver states the subject is unable to complete

    4. MDs opinion

    • Inability to complete follow up visits due to transportation issues
    1. No access to transportation (ie. does not have vehicle)

    2. Live > 2 hours from LLUH

    3. Does not have financial means

    • Congenital anomalies
    1. Bladder Exstrophy

    2. Connective tissue disease

    3. Neovaginal prolapse

    4. Prolapse of sex change vagina

    • Chronic pelvic pain
    1. 6 months of pelvic pain of undetermined origin

    2. not cyclic pain (eg. period pain or dysmenorrhea)

    3. Patient has comorbidities of CPP

    4. Fibromyalgia

    5. Interstitial cystitis

    6. Vulvodynia

    • Contraindications to Mesh,
    1. Opposition to the use mesh (ie. due to religious beliefs)

    2. History of mesh complications in past

    • Pregnant or planning to become pregnant during the study period.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Loma Linda University URO/GYN Loma Linda California United States 92354

    Sponsors and Collaborators

    • Loma Linda University

    Investigators

    • Principal Investigator: Sam Siddighi, Loma Linda University Health Care

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Loma Linda University
    ClinicalTrials.gov Identifier:
    NCT02800512
    Other Study ID Numbers:
    • 5160158
    First Posted:
    Jun 15, 2016
    Last Update Posted:
    Sep 20, 2021
    Last Verified:
    Sep 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Keywords provided by Loma Linda University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 20, 2021